Kura Oncology, Inc.
HealthcareNASDAQ:KURA · NASDAQ Global Select
+$0.19 today
Vol 1.29M · Avg 2.09M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $39.1M |
| Short-term Investments | $541.7M |
| Receivables | $13.6M |
| Inventory | $843.0K |
| Other Current | $28.5M |
| Total Current Assets | $623.8M |
| PP&E (Net) | $14.8M |
| Other Non-current | $14.0M |
| Total Non-current Assets | $28.8M |
| Total Assets | $652.6M |
Analysis
Selected assets total $652.6M for Latest. The largest visible component is Short-term Investments at $541.7M, about 83.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $149.1M -33.6% | $224.5M +501.5% | $37.3M -28.0% | $51.8M -42.9% | $90.7M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $518.1M +3.0% | $502.9M +30.1% | $386.6M +0.1% | $386.2M -9.6% | $427.3M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $12.6M | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $413.0K | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $28.4M +62.9% | $17.4M +104.5% | $8.5M +1.0% | $8.4M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $708.7M -4.9% | $744.8M +72.2% | $432.5M -3.1% | $446.4M -14.5% | $522.3M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $15.2M +102.5% | $7.5M -15.4% | $8.9M +38.7% | $6.4M -22.6% | $8.2M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $14.5M +85.4% | $7.8M +3.2% | $7.6M +117.3% | $3.5M -0.5% | $3.5M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $29.7M +93.7% | $15.3M -6.8% | $16.5M +66.5% | $9.9M -16.0% | $11.8M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $738.4M -2.9% | $760.2M +69.3% | $448.9M -1.6% | $456.3M -14.6% | $534.1M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.0M +241.5% | $1.5M -36.1% | $2.3M +50.0% | $1.5M -52.6% | $3.2M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $1.3M -51.0% | $2.6M | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $2.1M | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $24.3M | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $110.4M +530.8% | $17.5M +33.1% | $13.2M +27.7% | $10.3M +30.0% | $7.9M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $117.0M +48.6% | $78.7M +123.2% | $35.3M +46.6% | $24.1M +7.1% | $22.5M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $9.7M +40.4% | $6.9M -25.9% | $9.3M +1.9% | $9.2M | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $424.9M +67.3% | $253.9M | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $3.2M +76.3% | $1.8M +154.6% | $705.0K +166.0% | $265.0K -29.3% | $375.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $447.3M +67.0% | $267.8M +1533.1% | $16.4M +37.0% | $12.0M +140.0% | $5.0M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $564.2M +62.8% | $346.5M +570.7% | $51.7M +43.4% | $36.0M +31.3% | $27.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $9.0K +12.5% | $8.0K +14.3% | $7.0K +0.0% | $7.0K +0.0% | $7.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.2B -31.1% | -$895.4M -24.1% | -$721.4M -26.8% | -$568.8M -31.4% | -$433.0M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $1.0M +34.0% | $764.0K +160.1% | -$1.3M +84.2% | -$8.0M -349.0% | -$1.8M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $174.1M -57.9% | $413.6M +4.1% | $397.3M -5.5% | $420.3M -17.0% | $506.6M | $9.1B | $7.7B | $3.3B |
| Total Debt | $20.5M +23.3% | $16.6M -3.5% | $17.2M +22.6% | $14.0M +104.0% | $6.9M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$128.6M +38.1% | -$207.9M -933.2% | -$20.1M +46.7% | -$37.8M +54.9% | -$83.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
ProKidney Corp.
NASDAQ:PROK
$242.99M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does KURA have?
Kura Oncology, Inc. (KURA) reported $149.10M in cash and equivalents in fiscal 2025.
How much debt does KURA carry?
Kura Oncology, Inc. (KURA) reported $20.46M of total debt, with net debt of -$128,642,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.